China Pharma Holdings, a specialty pharmaceutical company, today announced that on July 15, 2022, the Company submitted a plan of compliance to NYSE American to address the deficiency in the Company's stockholders' equity as pointed out in the letter from the Exchange dated June 15, 2022.

As previously released in a press release dated June 22, 2022, according to the Letter, in order to maintain its listing, the Company must submit a plan of compliance by July 15, 2022 addressing how it intends to regain compliance with Section 1003(a)(iii) of the Company Guide by December 15, 2023.

Zhilin Li, China Pharma's Chairman and CEO, commented, "The staff of the NYSE American indicated that they could accept the plan of compliance. During the next 18 months grace period or by December 15, 2023, we will actively supply additional information as required by the Exchange, implement the plan and strive to regain compliance on stockholders' equity as required by the Exchange listing requirement under as soon as possible."